News
04-14-2010, 11:08 PM
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.
More... (http://www.news-medical.net/news/20100415/ErbB3-program-development-candidate-selection-triggers-245M-milestone-payment-to-AVEO-Pharmaceuticals.aspx)
More... (http://www.news-medical.net/news/20100415/ErbB3-program-development-candidate-selection-triggers-245M-milestone-payment-to-AVEO-Pharmaceuticals.aspx)